BCA
NBIX icon

Berman Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Berman Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$47K Buy
494
+83
+20% +$7.84K 0.01% 702
2021
Q2 		$39K Buy
411
+239
+139% +$22.9K 0.01% 671
2021
Q1 		$16K Buy
172
+12
+8% +$1.26K ﹤0.01% 865
2020
Q4 		$15K Sell
160
-3
-2% -$290 ﹤0.01% 764
2020
Q3 		$15K Sell
163
-13
-7% -$1.5K ﹤0.01% 671
2020
Q2 		$20K Buy
176
+13
+8% +$1.44K 0.01% 540
2020
Q1 		$13K Buy
163
+22
+16% +$2.15K ﹤0.01% 606
2019
Q4 		$15K Sell
141
-15
-10% -$1.57K ﹤0.01% 616
2019
Q3 		$14K Buy
156
+15
+11% +$1.4K ﹤0.01% 621
2019
Q2 		$11K Buy
141
+65
+86% +$5.34K ﹤0.01% 696
2019
Q1 		$6K Buy
76
+71
+1,420% +$5.93K ﹤0.01% 824
2018
Q4 		$0 Buy
+5
New +$479 ﹤0.01% 1210

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Berman Capital Advisors's NBIX Position: Q3 2021 in Review

Berman Capital Advisors increased its Neurocrine Biosciences (NBIX) stake by 20% in Q3 2021, buying an estimated $7.84K and bringing the position to 494 shares worth $47K. The position accounts for 0.01% of the portfolio, ranked #702.

Berman Capital Advisors first reported a position in NBIX in Q4 2018 and has held it in 12 quarters since. 396 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

  • Berman Capital Advisors held 494 shares of Neurocrine Biosciences worth $47K as of Q3 2021.
  • Berman Capital Advisors bought 83 Neurocrine Biosciences shares in Q3 2021, an estimated $7.84K.
  • Neurocrine Biosciences made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #702 holding.
  • Berman Capital Advisors first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 12 quarters since.
  • 396 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.